Stoke Therapeutics, Inc. Investing Cash Flow
Stoke Therapeutics, Inc. (STOK) reported Investing Cash Flow of $59.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-03
- Stoke Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $9.02M.
- Stoke Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $50.69M, a 271.88% increase year-over-year.
- Stoke Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$61.06M, a 7555.56% decline year-over-year.
- Stoke Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $9.09M.
- Stoke Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$186.81M.
- Stoke Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$107.47M, a 201.44% decline from fiscal 2023.
- Stoke Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $105.95M.
- Stoke Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$45.88M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $59.71M 10-Q · filed 2026-08-03 | -$1.35M derived: sum of 3 quarters · filed 2026-08-03 | $7.75M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $50.69M 10-Q · filed 2026-05-07 | -$10.37M derived: sum of 2 quarters · filed 2026-05-07 | -$1.27M derived: sum of 3 quarters · filed 2026-05-07 | -$149.75M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$61.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$51.97M derived: sum of 2 quarters · filed 2026-03-16 | -$200.44M derived: sum of 3 quarters · filed 2026-08-03 | -$186.81M 10-K · filed 2026-03-16 |
| 2025-09-30 | $9.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$139.38M derived: sum of 2 quarters · filed 2026-08-03 | -$125.75M 10-Q · filed 2025-11-04 | -$124.93M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$148.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$134.84M 10-Q · filed 2026-08-03 | -$134.03M derived: sum of 3 quarters · filed 2026-08-03 | -$164.03M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $13.63M 10-Q · filed 2026-05-07 | $14.45M derived: sum of 2 quarters · filed 2026-05-07 | -$15.55M derived: sum of 3 quarters · filed 2026-05-07 | -$103.83M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $819.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$29.18M derived: sum of 2 quarters · filed 2026-03-16 | -$117.46M derived: sum of 3 quarters · filed 2026-03-16 | -$107.47M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$30.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$118.28M derived: sum of 2 quarters · filed 2025-11-04 | -$108.29M 10-Q · filed 2025-11-04 | -$93.52M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$88.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$78.29M 10-Q · filed 2025-08-12 | -$63.52M derived: sum of 3 quarters · filed 2025-08-12 | -$48.90M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $9.99M 10-Q · filed 2025-05-13 | $24.76M derived: sum of 2 quarters · filed 2025-05-13 | $39.38M derived: sum of 3 quarters · filed 2025-05-13 | $62.85M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $14.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $29.39M derived: sum of 2 quarters · filed 2025-03-18 | $52.86M derived: sum of 3 quarters · filed 2025-03-18 | $105.95M 10-K · filed 2025-03-18 |
| 2023-09-30 | $14.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $38.09M derived: sum of 2 quarters · filed 2024-11-05 | $91.17M 10-Q · filed 2024-11-05 | $113.67M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $23.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $76.56M 10-Q · filed 2024-08-07 | $99.05M derived: sum of 3 quarters · filed 2024-08-07 | $166.31M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $53.09M 10-Q · filed 2024-05-06 | $75.58M derived: sum of 2 quarters · filed 2024-05-06 | $142.84M derived: sum of 3 quarters · filed 2024-05-06 | $142.99M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $22.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $89.75M derived: sum of 2 quarters · filed 2024-03-25 | $89.90M derived: sum of 3 quarters · filed 2024-03-25 | -$45.88M 10-K · filed 2024-03-25 |
| 2022-09-30 | $67.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $67.41M derived: sum of 2 quarters · filed 2023-11-07 | -$68.37M 10-Q · filed 2023-11-07 | -$56.58M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$135.64M 10-Q · filed 2023-08-07 | -$123.84M derived: sum of 3 quarters · filed 2023-08-07 | -$129.10M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$135.78M 10-Q · filed 2023-05-04 | -$123.98M derived: sum of 2 quarters · filed 2023-05-04 | -$129.25M derived: sum of 3 quarters · filed 2023-05-04 | -$212.00M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $6.53M derived: sum of 2 quarters · filed 2023-03-06 | -$76.22M derived: sum of 3 quarters · filed 2023-03-06 | -$76.43M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$5.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$88.02M derived: sum of 2 quarters · filed 2022-11-14 | -$88.22M 10-Q · filed 2022-11-14 | -$88.31M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$82.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$82.96M 10-Q · filed 2022-08-08 | -$83.05M derived: sum of 3 quarters · filed 2022-08-08 | -$83.32M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$204.00K 10-Q · filed 2022-05-10 | -$294.00K derived: sum of 2 quarters · filed 2022-05-10 | -$563.00K derived: sum of 3 quarters · filed 2022-05-10 | -$644.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$359.00K derived: sum of 2 quarters · filed 2022-03-10 | -$440.00K derived: sum of 3 quarters · filed 2022-03-10 | -$1.05M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$269.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$350.00K derived: sum of 2 quarters · filed 2021-11-08 | -$960.00K 10-Q · filed 2021-11-08 | -$1.53M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$691.00K 10-Q · filed 2021-08-10 | -$1.26M derived: sum of 3 quarters · filed 2021-08-10 | -$1.84M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$610.00K 10-Q · filed 2021-05-10 | -$1.18M derived: sum of 2 quarters · filed 2021-05-10 | -$1.76M derived: sum of 3 quarters · filed 2021-05-10 | -$2.15M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | -$569.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$1.15M derived: sum of 2 quarters · filed 2021-03-09 | -$1.54M derived: sum of 3 quarters · filed 2021-03-09 | -$1.63M 10-K · filed 2021-03-09 |
| 2019-09-30 | -$583.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$975.00K derived: sum of 2 quarters · filed 2020-11-12 | -$1.06M 10-Q · filed 2020-11-12 | -$1.15M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$392.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$482.00K 10-Q · filed 2020-08-10 | -$565.00K derived: sum of 3 quarters · filed 2020-08-10 | -$1.08M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$90.00K 10-Q · filed 2020-05-15 | -$173.00K derived: sum of 2 quarters · filed 2020-05-15 | -$689.00K derived: sum of 3 quarters · filed 2020-05-15 | |
| 2018-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | -$599.00K derived: sum of 2 quarters · filed 2020-03-23 | -$925.00K 10-K · filed 2020-03-23 | |
| 2018-09-30 | -$516.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$842.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$326.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |